[PRESS RELEASE] – EDMONTON, Alberta, April 30, 2025 – Aurora Cannabis Inc., the Canadian-based leading global medical cannabis company, announced the completion of a multi-year investment of $3 million in improvements to its manufacturing facility in Pemberton, British Columbia. These upgrades are a combination of Aurora's proprietary high-performing genetics and state-of-the-art engineering design, which have resulted in optimal cultivation conditions, expanded output and superior product quality. The site has been renamed to Aurora Alpine—a testament to the site reaching its highest potential and to reflect the facility overlooking Mount Currie in the Pemberton Valley.
"Over the last three years, the investments we've made into this facility have resulted in doubling the yield and potency, reaching a record 33.7%," said Alex Miller, executive vice president of Operations and Supply Chain at Aurora. "The name Aurora Alpine reflects our commitment to achieving the highest degree of excellence at a site that's driven by industry-leading genetic technology and backed by a world-class team that make it all possible."
The former Whistler Medical Marijuana Co. site was licensed in 2019 and was built on a legacy of producing award-winning cannabis. The GACP-certified facility enables Aurora to expand its global reach by exporting premium medical cannabis produced from the Aurora Alpine site internationally.
Aurora continues to advance the frontiers of operational excellence through the integration of cutting-edge cultivation technologies and proprietary genetics. These advancements have not only increased manufacturing capabilities but have also set new industry standards for operational efficiency and cultivation precision. These continuous improvements are what solidifies Aurora as a global leader that continues to shape the future of the cannabis industry.
